Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas

  • Authors:
    • Takahide Taguchi
    • Yasumasa Kato
    • Yuh Baba
    • Goshi Nishimura
    • Yuji Tanigaki
    • Choichi Horiuchi
    • Idumi Mochimatsu
    • Mamoru Tsukuda
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/or.11.2.421
  • Pages: 421-426
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Regression of tumor mass by chemotherapy is caused by growth suppression and/or apoptosis of tumor cells. Therefore, expression levels of cell cycle molecules and apoptosis should be predictive markers for the efficacy of a drug. In the present study, the relationship between expression of molecules in the cell cycle and apoptosis and chemosensitivity was investigated in head and neck squamous cell carcinoma cell lines. Expression of p53, p21, p27, cyclin D1, cyclin E, and Bax in 17 such cell lines were analyzed by Western blot analysis. The concentrations of four chemotherapeutic agents (cisplatin, 5-FU, vincristine, and paclitaxel) resulting in 50% cell growth inhibition were calculated as IC50 values for each cell line. Cell cycle analysis was performed using a FACScan flow cytometer. Cells with strong expression of p21, p27, or Bax showed significantly higher sensitivity to cisplatin, and cells with strong expression of Bax or weak expression of cyclin E showed significantly higher sensitivity to paclitaxel. Cisplatin most effectively killed cells expressing both p21 and p27 or either at G1 phase. Though the assessments of p21, p27, Bax, and cyclin E expression in tumor tissues have been reported to be useful as prognostic factors in head and neck squamous cell carcinoma, these correlations might not only describe the malignant biological behavior of the tumor, but also the response to chemotherapy. Furthermore, p21/p27 expression might be a useful guide for the choice of chemotherapeutic agents.

Related Articles

Journal Cover

February 2004
Volume 11 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Taguchi T, Kato Y, Baba Y, Nishimura G, Tanigaki Y, Horiuchi C, Mochimatsu I and Tsukuda M: Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol Rep 11: 421-426, 2004.
APA
Taguchi, T., Kato, Y., Baba, Y., Nishimura, G., Tanigaki, Y., Horiuchi, C. ... Tsukuda, M. (2004). Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncology Reports, 11, 421-426. https://doi.org/10.3892/or.11.2.421
MLA
Taguchi, T., Kato, Y., Baba, Y., Nishimura, G., Tanigaki, Y., Horiuchi, C., Mochimatsu, I., Tsukuda, M."Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas". Oncology Reports 11.2 (2004): 421-426.
Chicago
Taguchi, T., Kato, Y., Baba, Y., Nishimura, G., Tanigaki, Y., Horiuchi, C., Mochimatsu, I., Tsukuda, M."Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas". Oncology Reports 11, no. 2 (2004): 421-426. https://doi.org/10.3892/or.11.2.421